Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pasithea Therapeutics Corp. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 matter is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a highly concentrated prosecution footprint at this stage. The busiest examiner for the portfolio is CHAO, ALLEN, who is responsible for the 1 busiest examiner pending case currently on record.
Practitioners should note that the presence of only 1 distinct examiner and 1 distinct art unit suggests a very narrow focus for the company's current patent activities. Because CHAO, ALLEN handles the only pending matter, the outcome of this specific interaction will define the immediate success of the portfolio in this sector. The lack of diversity in art units means that the company is not currently facing varied procedural hurdles across different sections of the patent office. Strategy should be tailored to the specific examination history of the assigned examiner to ensure a favorable result for this 1 pending office action. This focused approach allows for a very specific and targeted legal strategy for the company's current patent interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19559551 | SOLID FORMS COMPRISING (5R,6S)-10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | Mar 06, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial